FDA Sets Hierarchy for Biosimilars Evidence

July 22, 2014

McDermott+Consulting

With the FDA issuing a draft guidance – years in the making – on biosimilars, Paul Radensky discusses the categorization of clinical pharmacological data a company will have to submit as evidence of biosimilarity and how the data expected is similar for other types of products.

To read the full article, click here.

Previous Post / Next Post
beakernav X1E2BFA62-BFCE-43C1-B777-27E3E5216018medical bagoriginal analysis +external linkpdf downloadstethoscope